Safety and efficacy of pemigatinib in patients with cholangiocarcinoma: a systematic review.

ABSTRACT:

Background

Cholangiocarcinoma (CCA) is an aggressive bile duct cancer with limited therapeutic options and poor prognosis. pemigatinib, a selective FGFR inhibitor, has emerged as a promising targeted therapy for CCA patients harboring FGFR2 fusions or rearrangements. This systematic review evaluated the safety and efficacy of pemigatinib in this patient population.

Methods

A comprehensive systematic review was conducted across PubMed, Scopus, Embase, Cochrane Library, and Web of Science to identify studies investigating pemigatinib in CCA patients. Five studies involving a total of 459 patients met the inclusion criteria.

Results

Pemigatinib demonstrated an overall objective response rate (ORR) of 43.2%, with a complete response (CR) achieved in 3% of pa

SUBMITTER: Rasool W 

PROVIDER: S-EPMC12078806 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature